LTR Pharma broadens Australian men’s health platform with exclusive KYZATREX pilot deal
LTR Pharma (ASX:LTP) has executed an exclusive pilot commercialisation agreement with Marius Pharmaceuticals, Inc. for KYZATREX®, an FDA-approved oral testosterone therapy already commercially available in the United States.
Initial stock of KYZATREX has now arrived in Australia. Early patient access will be facilitated through the TGA Special Access Scheme (SAS), the regulatory channel that allows medical practitioners to prescribe unapproved therapeutic goods for individual patients.
The strategic logic centres on efficiency. KYZATREX is intended to leverage the prescriber base, telehealth channels and distribution infrastructure LTR Pharma has already built for its erectile dysfunction (ED) product SPONTAN®.
Following the initial evaluation phase, LTR Pharma holds a right to negotiate an exclusive Australian licensing agreement for the product. This is a right to negotiate, not a licence already in hand.
When big ASX news breaks, our subscribers know first
Inside the KYZATREX agreement
The deal establishes an initial exclusive pilot commercialisation phase in Australia, supported by an inventory commitment sized to establish prescriber demand and operational processes.
During a six-month evaluation period, LTR Pharma will retain exclusivity in Australia. Over that window, LTR Pharma and Marius will evaluate physician adoption, patient demand and the feasibility of pursuing a potential TGA registration pathway.
Following the evaluation period, LTR Pharma has a right to negotiate an exclusive licence for KYZATREX in Australia. Importantly for shareholders, the agreement is not expected to materially affect the Company’s financial position.
KYZATREX is not registered by the TGA. The Special Access Scheme is the mechanism enabling prescribing during this initial phase, applying to unapproved therapeutic goods on an individual-patient basis in accordance with applicable TGA requirements.
| Feature | Detail |
|---|---|
| Partner | Marius Pharmaceuticals, Inc. |
| Product | KYZATREX® oral testosterone undecanoate |
| Agreement type | Exclusive pilot commercialisation |
| Evaluation period | Six months |
| Access pathway | TGA Special Access Scheme |
| Future option | Right to negotiate exclusive Australian licence |
Why testosterone therapy matters for investors
Testosterone deficiency affects a range of physiological functions and, according to the Company, remains underdiagnosed and undertreated in Australia.
Its impact spans several areas:
- Energy levels
- Mood
- Muscle mass
- Bone density
- Sexual function
Most testosterone replacement therapy in Australia is currently delivered by injection, gel, patch or implant. An oral capsule positions KYZATREX as a differentiated and potentially more convenient alternative for patients and prescribers.
KYZATREX uses a proprietary formulation designed to facilitate lymphatic absorption, reducing the first-pass hepatic metabolism associated with earlier oral testosterone therapies. According to the Company, the product is supported by clinical data demonstrating its ability to restore testosterone levels in men with testosterone deficiency.
The investment angle rests on adjacency. Testosterone deficiency and erectile dysfunction can present within the same men’s health consultation, involving overlapping prescribers and patient-access channels. That overlap makes KYZATREX a low-friction extension of the platform LTR Pharma has built around SPONTAN®.
A complementary fit with LTR’s existing platform
For investors, the appeal is capital efficiency. The agreement offers a route to expand the men’s health portfolio using clinical networks, telehealth channels and distribution infrastructure already established.
The two companies are also already connected through shared clinical advisers. Dr Andrew Y. Sun, M.D. and Dr Amy Pearlman, M.D. each serve on LTR Pharma’s Scientific Advisory Board (see ASX announcements dated 11 and 18 August 2025) and on Marius’ urology advisory board.
Notably, this expansion is being pursued alongside LTR Pharma’s core ED programs, not in place of them.
Amit Shah, COO of Marius Pharmaceuticals
“We are excited to partner with LTR Pharma to introduce KYZATREX in Australia. LTR’s established clinical networks and growing telehealth channels make them a strong partner to support patient access and physician adoption in this important market. We look forward to working together to expand access to KYZATREX and address unmet needs in testosterone deficiency.”
Next steps and core program momentum
LTR Pharma will commence initial market development activities, including:
- Facilitating initial patient access through compliant SAS pathways
- Engaging and educating an initial group of Australian men’s-health KOLs and prescribers
- Evaluating physician adoption and patient demand
- Working with Marius to assess the potential pathway toward TGA registration in Australia
The pilot sits within a broader pipeline context. The Company noted ROXUS® moving toward U.S. commercial launch through SHED and Strive, the final SPONTAN Phase II report expected shortly, and planning underway for the pivotal SPONTAN Phase III study in 2027.
The ROXUS U.S. telehealth distribution agreement with Shed Holdings commits to not less than 150,000 units in the first 12 months following Commercial Launch, with ROXUS already live on the Mavrox men’s health platform and a patient waitlist building ahead of a formal launch date.
Lee Rodne, Executive Chairman, LTR Pharma
“We are pleased to partner with Marius to introduce KYZATREX in Australia. As an FDA-approved oral testosterone therapy, KYZATREX represents a complementary opportunity to broaden our men’s health portfolio by leveraging the clinical networks, telehealth channels and commercial infrastructure we have already established through SPONTAN. At the same time, we remain focused on execution of our core programs, with ROXUS moving toward U.S. commercial launch through SHED and Strive, the final SPONTAN Phase II report expected shortly and planning underway for the pivotal Phase III study in 2027.”
The KYZATREX agreement adds a further layer to LTR Pharma’s men’s health strategy, broadening the portfolio through an FDA-approved therapy while the Company continues advancing its core intranasal ED pipeline.
Don’t Miss the Next Healthcare Breakout on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000+ subscribers already rely on it to stay ahead of market-moving announcements. Click the “Free Alerts” button at Big News Blast to make sure the next major healthcare development reaches you before the market moves.